Overview

This trial is active, not recruiting.

Conditions uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, scleritis, clinically significant macular edema
Treatment h.p. acthar subcutaneous gel injection
Phase phase 4
Sponsor Tampa Bay Uveitis Center, LLC
Collaborator Mallinckrodt
Start date July 2016
End date January 2017
Trial size 6 participants
Trial identifier NCT02764697, TBUC 10012015

Summary

Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory reaction involving ocular tissue and vasculature. The inflammation usually causes pain, redness, photophobia and blurred vision. This inflammation, is typically treated with regional or systemic therapy. The regional therapy typically consists of topical corticosteroids or periocular or regional corticosteroids. Regional therapy can lead to a steroid response glaucoma, which is increased intraocular pressure.This pilot study aims to evaluate the possible effectiveness of H.P. Acthar in patients with active ocular inflammatory disease, and currently on treatment for glaucoma or have a history of glaucoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Other)
For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
h.p. acthar subcutaneous gel injection Acthar
Subcutaneous injection twice weekly

Primary Outcomes

Measure
Resolution of Inflammation: Anterior Uveitis
time frame: 12 weeks
Resolution of Inflammation: Retinal Vasculitis
time frame: 12 weeks
Resolution of Inflammation:Intermediate Uveitis: Photographic haze reduced to grade 0 or down 2 steps documented with fundus photography
time frame: 12 Weeks
Resolution of Inflammation: Clinically Significant Uveitic Macular Edema: Clinical improvement of macular edema with optical coherence tomography (OCT), which measures retinal thickness; documentation of central foveal thickness < 300 microns
time frame: 12 weeks
Resolution of Inflammation: Scleritis: 2 step decrease or down to grade 0 improvement of with photographic documentation
time frame: 12 weeks
Resolution of Inflammation: Resolution of retinal and choroidal infiltrate with photographic documentation
time frame: 12 weeks

Secondary Outcomes

Measure
Change in visual acuity
time frame: 12 and 24 weeks

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Subject has the ability to understand and sign the informed consent document - Subject is 18 years of age or older - Subject can be male or female - Subject has negative Purified Protein Derivative (Tuberculosis skin test) or quantiferon TB Gold Test (blood test for TB) testing done in 3 months - Subject has active ocular inflammation in at least one eye - Subject has visual acuity in at least one eye of 20/400 or better. - Subject has a history of glaucoma or has actively treated glaucoma - Subject is willing and able to comply with the study procedures - Female subjects of childbearing potential must not be pregnant or breast-feeding, must have a negative pregnancy test at screening and must be willing to undergo pregnancy testing throughout the study Exclusion Criteria: - Subject has any ocular infection - Subject has any systemic infection - Participant has documented immunocompromised or immune-incompetent state - Subject has any ocular co-morbidity than prevents assessment of intraocular inflammation - Subject has had any intra-ocular surgery in previous 6 weeks - Subject has any planned elective surgery ocular or systemic during study duration - Subject is pregnant or breast-feeding - Subject had a recent vaccination with live or attenuated vaccines - Subject has a sensitivity to Porcine derived proteins - Subject has a medical history which is a contraindication to receiving H.P. Acthar

Additional Information

Official title Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects
Principal investigator Grace L Clarke
Description Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory reaction involving ocular tissue and vasculature. The inflammation usually causes pain, redness, photophobia and blurred vision. H.P Acthar Gel stimulate the adrenal cortex to secrete cortisol. Additionally H.P. Acthar gel is also reported to bind to melanocortin receptors. Melanocortin receptor activation has been shown to exert marked anti-inflammatory and immune-modulatory effects in animal studies, by modulating pro inflammatory cytokines, followed by induction of anti- inflammatory mediators and subsequent leukocyte migration. Specifically melanocortins down regulate Tumor Necrosis Factor (TNF) alpha, Interleukin (IL) -2, Interferon gamma and T-cell proliferation and upregulates IL-10 and regulatory T cells. For this reason H.P. Acthar is an approved treatment for ocular inflammatory disease. Ocular inflammatory disease is typically treated with regional or systemic therapy. The regional therapy typically consists of topical corticosteroids or periocular or regional corticosteroids. Regional therapy can lead to a steroid response glaucoma, which is increased intraocular pressure.This pilot study aims to evaluate the possible effectiveness of H.P. Acthar in patients with active ocular inflammatory disease, and currently on treatment for glaucoma or have a history of glaucoma. Subjects will be treated with H P Acthar subcutaneous gel, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses with the same cumulative units to be administered, using the approved route, with the option to do 4 additional doses if resolution is incomplete. This will be a prospective open-label, non-randomized pilot study: 12 week treatment for active non-infectious uveitis, endpoint assessment and safety assessment; additional 12 week assessment for uveitis activity/quiescence and safety assessment.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Tampa Bay Uveitis Center, LLC.